Topical questions of import substitution were discussed at a recent meeting of Expert Council on Development of Biotechnical, Pharmaceutical and Medical Industry under Duma Industry Committee. Particular attention was paid to maintaining the balance between protectionist measures and interests of patients.
Meeting participants, representing federal executive authorities, educational institutions, not-for-profit organizations, patient communities and manufacturers remarked growth of Russian pharma industry and its increased attractiveness for international investors. Talking about increased share of Russian drugs in the local market (40 to 28.5%), Department of Development of Biotechnical, Pharmaceutical and Medical Industry, Ministry of Industry and Trade of the Russian Federation Olga Kolotilova remarked that in the recent five years 22 new production sites in the most socially significant areas have been created.
Besides, the need for changing stereotypes of most consumers, who are confident that “foreign products are better”. For that purpose community should be kept informed about achievements of local pharma industry and avoid distortion of information. Patient should understand, that Russian drugs are not inferior, and sometimes even superior to imported drugs for quality.
That is why meeting participants recommended to the Ministry of Justice of the Russian Federation to check the presence of not-for-profit organizations, representing interests of international pharma manufacturers in the list of not-for-profit organizations acting as foreign agents, and recommend mass media to publish information on achievements of local pharmaceutical industry.